Welcome to the PharmCast Research Store. Gain access to market leading research in your industry. You can browse through the portfolio of reports below or enter keywords in the search box to find the information you have been looking for.
  • Browse Reports & Briefs
  • Browse Company Profiles
  • Browse Industry Profiles
  • Latest News
Number of Employees

< 250 (30)

250 - 999 (22)

1,000 - 2,499 (20)

2,500 - 4,999 (29)

5,000 - 9,999 (56)

10,000 - 49,999 (113)

50,000+ (40)

Annual Revenue US$m

< 50 (19)

50 - 99 (7)

100 - 199 (8)

200 - 499 (20)

500 - 999 (11)

1,000 - 1,999 (45)

2,000+ (189)

Top stories

Derma Sciences reports higher Q1 net loss, provides guidance for 2015

Derma Sciences, Inc., a provider of products for management of acute and chronic wounds, has reported that net loss for the first quarter ended March 31, 2015 was $10.61 million, or $0.42 loss per share, compared to a net loss of $10.27 million, or $0.46 loss per share, for the same quarter ended March 31, 2014. For 2015, the company expects net sales to be around $88.1 million...more >>

Halozyme Therapeutics reports lower Q1 net loss, reiterates guidance for 2015

Halozyme Therapeutics, Inc., a biotechnology company, has reported that net loss for the first quarter ended March 31, 2015 was $15.11 million, or $0.12 loss per share, compared to a net loss of $26.55 million, or $0.22 loss per share, for the same quarter ended March 31, 2014. For 2015, the company has reiterated its net revenue guidance range to be between $85 million and $95 million...more >>

Sarepta Therapeutics Q1 net loss increases

Sarepta Therapeutics, Inc., a medical research and drug development company, has reported that net loss for the first quarter ended March 31, 2015 was $61.56 million, or $1.49 loss per share, compared to a net loss of $28.27 million, or $0.75 loss per share, for the same quarter ended March 31, 2014...more >>

Stellar Biotechnologies Q2 net loss decreases

Stellar Biotechnologies, Inc. has reported that net loss for the second quarter ended March 31, 2015 was $426,164, or $0.01 loss per share, compared to a net loss of $1.43 million, or $0.02 loss per share, for the same quarter ended March 31, 2014...more >>

More headlines

Depomed reports net loss for Q1, updates guidance for 2015
Published 26 May 2015 - MarketLine

Repros Therapeutics Q1 net loss decreases
Published 26 May 2015 - MarketLine

ImmuCell reports net income for Q1
Published 26 May 2015 - MarketLine

InSite Vision Q1 net loss decreases
Published 26 May 2015 - MarketLine

Antares Pharma Q1 net loss decreases
Published 26 May 2015 - MarketLine

Synta Pharmaceuticals Q1 net loss decreases
Published 26 May 2015 - MarketLine

Kaiser Permanente appoints COO for South Bay Medical Center
Published 26 May 2015 - MarketLine

Sumitomo Dainippon reports lower annual net income, provides outlook for H1
Published 26 May 2015 - MarketLine

Florida Blue and TBIH launch accountable care program
Published 26 May 2015 - MarketLine

Vermillion Q1 net loss increases
Published 26 May 2015 - MarketLine

Actavis reports net loss for Q1, provides outlook for 2015
Published 26 May 2015 - MarketLine

Browse all news >>